PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab-paclitaxel-treated advanced triple-negative breast cancer - Rugo, Hope S.; Loi, Sherene; Adams, Sylvia; Schmid, Peter; Schneeweiss, Andreas; Barrios, Carlos H; Iwata, Hiroji; Diéras, Véronique; Winer, Eric P; Kockx, Mark M; Peeters, Dieter; Chui, Stephen Y; et al. (Journal of the National Cancer Institute, 2021)
Gesehen am 05.10.2022